Summit Therapeutics (SMMT) Is Losing Wall Street’s Confidence

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 10 Stocks Investors Are Fleeing.

Summit Therapeutics extended its losing streak to a 5th consecutive day on Tuesday to hit a new 52-week low, as investors resumed selling positions after the Food and Drug Administration (FDA) declined its biologics license application for its lung cancer treatment.

In intraday trading, the stock dropped to a new record low of $10.53 before ending the day down 9.73 percent at $10.67 apiece.

Photo by Tima Miroshnichenko on Pexels

In a regulatory filing on Monday, Summit Therapeutics Inc. said that the FDA rejected its BLA after determining that substantial evidence of effectiveness was not established amid the absence of a statistically significant improvement in enrolled patients’ overall survival.

Additionally, the FDA indicated that data on progression-free survival (PFS) without any improvement in overall survival do not support a positive benefit-risk profile.

The BLA was based on Summit Therapeutics Inc.’s data from its double-blind Phase 3 clinical trial, which aimed to study Ivonescimab in combination with chemotherapy, where PFS—its primary endpoint—was met.

The study found that Ivonescimab combined with chemotherapy was well-tolerated with no new safety signals and comparable rates of discontinuation and death.

The study found that Ivonescimab combined with chemotherapy was well-tolerated with no new safety signals and comparable rates of discontinuation and death.

However, 16 patients in the Ivonescimab group and 11 patients in the placebo group discontinued due to adverse effects.

Nine patients died, including four from the Ivonescimab plus chemotherapy arm group, and five in the chemotherapy alone.

“We are disappointed for patients and their families awaiting additional treatment options in this setting,” Chairman and CEO Robert Duggan said.

READ NEXT: Forget Nvidia: 10 Stocks Wall Street is Betting on Right Now and Buy Alert: 10 Stocks Analysts Upgraded on Friday

Follow Insider Monkey on Google News.